Abstract:Cancer, a leading cause of death in the human population today, is generally being treated with chemotherapeutic methods, which have adverse toxic side effects. Immunotherapy represents an attractive alternative to common treatment since it is based on activation of host immune system. In current studies we assessed the ability the of AAV vectors expressing antigen to activate a specific T-cell response in vivo. The ovarian albumin (OVA), commonly used in mouse models as an antigen for immunization studies was used to evaluate immune response. AAV6-WT-OVA and capsid-optimized AAV6-S662V+T492V-OVA vectors were injected intramuscularly in C57BL/6 mice with a dose of 5×10e11 vgs/mouse. Enchased green fluorescent protein (AAV6-EGFP) was used as negative control. In two weeks after injection, blood was collected and a number of OVA-specific T-cells were analyzed by stain with iTAg MHC Class I Murine Tetramer. The data shown suggest that the administration of AAV vectors expressing OVA led to a robust activation (approximately 9%) of specific T-cells compared to the mock and AAV-WT treated animals (less than 1%). Next, we evaluated the killing ability of these OVA specific T-cell. Splenocytes from C57BL/6 mice i.m. injected with AAV6-WT and AAV6-mutant vectors were isolated in 14 days after injection. OVA-CD8 cells were expanded in vitro in the presence of a predominant for C57BL/6 mice, SIINFEKL peptide. Stimulated T-cells were used for killing assay against mouse prostate cell line RM1 stably expressing OVA. Two-color fluorescence assay of cell-mediated cytotoxicity was used as described above to estimate percentage of dead/alive target cells and generate a killing curve with different effectors to target cell ratio. Results of these experiments suggest that OVA-CD8 cells isolated from mice injected with AAV-S662V+T492V-OVA vectors have higher killing activity compared with OVA-CD8 cells from AAV-WT-OVA injected mice. Control T-cell do not show significant cytotoxicity which eliminates the possibility of autoreactive response. Finally, we evaluated the ability of capsid-optimized AAV6 vectors to initiate a protective anti-cancer immune response. Prostatic acid phosphatase (PAP), a gene up regulated in both human and mouse prostate cancer, was used as a specific target. C57BL/6 mouse subcutaneously injected prostate cancer cell line, RM1, was used as an animal model. We genetically modified this cell line for a stable expression of firefly luciferase (FLuc) to monitor progression of tumor growth in live animals. First, animals were immunized with AAV6-S663V+T492-PAP or AAV6-WT-PAP vectors. Two weeks later mice were challenged with RM1-FLuc cells by subcutaneous injection. The effect of treatment on tumor growth was evaluated by whole body life imaging. Results indicate suppression of tumor growth by AAV6-S663V+T492-PAP for approximately four weeks in comparison to one week and two weeks for negative control AAV6-GFP and AAV6-WT-PAP treated mice, respectively. In conclusion, successful inhibition of tumor growth in this artificial animal model would set the stage for potential clinical application.

Adenoviral vector containing wild-type p16 suppresses prostate cancer growth and prolongs survival by inducing cell senescence

[Anti-Prostate Cancer Activity of Survivin-T34A Mutant in Vitro and in Vivo].

Autoregulated expression of p53 from an adenoviral vector confers superior tumor inhibition in a model of prostate carcinoma gene therapy

Arg-Gly-Asp (Rgd)-Modified E1A/E1B Double Mutant Adenovirus Enhances Antitumor Activity in Prostate Cancer Cells in Vitro and in Mice

Adenoviral Vector for Enhanced Prostate Cancer Specific Transferrin Conjugated Drug Targeted Therapy

Characterization of Adenoviral Transduction Profile in Prostate Cancer Cells and Normal Prostate Tissue.

Experimental Study in Vitro on Gene Therapy for Prostate Cancer with Recombinant Adenoviral Vector Carrying LRIG1 Gene Driven by Survivin Promoter

P16 Gene Expression Mediated by Adenovirus and Its Effect on Cell Cycle Arrest

Adenovirally transferred p16INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death

Adenovirus-mediated Transfer of P53 and P16 Inhibiting Proliferating Activity of Human Bladder Cancer Cell EJ in Vitro and in Vivo

Adenovirus-mediated Wild-Type P53 Expression Suppresses Growth of Lung Adeno-Carcinoma Cells

Adenovirus-mediated herpes simplex virus thymidine kinase gene therapy for experimental prostate cancer

In vitro and in vivo adenovirus-mediated p53 and p16 tumor suppressor therapy in ovarian cancer.

Development of Provenge for Prostate Carcinoma Therapy

Selective and Augmented Β-Glucuronidase Expression Combined with DOX-GA3 Application Elicits the Potent Suppression of Prostate Cancer.

Raav-Delivered PTEN Therapeutics for Prostate Cancer

Abstract 4102: Treatment with androgen receptor targeting vaccines provides an overall survival benefit in AR-V7 expressing tumor models

Abstract 4778: Development of self-amplifying RNA vaccines targeting prostate tissue-restricted and tumor-associated antigens

Combination of cabazitaxel and p53 gene therapy abolishes prostate carcinoma tumor growth

Adenovirus-mediated Restoration of Expression of the Tumor Suppressor Gene DLC1 Inhibits the Proliferation and Tumorigenicity of Aggressive, Androgen-Independent Human Prostate Cancer Cell Lines: Prospects for Gene Therapy

221. the Utilization of Capsid-Optimized Adeno-Associated Virus (AAV) Vectors for Cancer Immunotherapy